Discovery, regulation and function of the PI 3-Kinase and AKT pathway in cancer

Value of the Information & Strength of the Argument

The talk provides valuable insights into the PI3K/AKT pathway, combining established knowledge with recent unpublished findings from the speaker’s lab. The argumentation is solid, supported by references to key discoveries and clinical trials. The speaker effectively explains the rationale for new therapeutic approaches, such as ADCs and PROTACs, and highlights the importance of combination strategies. However, some claims about unpublished results and drug development are not independently verifiable, and the talk is primarily an expert opinion rather than a systematic review.

Scientific Rigor, Source Quality, Title Accuracy

The talk demonstrates high scientific rigor, with the speaker citing key papers and clinical trials. The sources mentioned include seminal works by Cantley, Parsons, Dixon, and others, as well as recent clinical trials. The title accurately reflects the content. The speaker is a recognized expert, and the content aligns with current scientific understanding. However, as a webinar, it lacks formal citation of all claims, and some statements about unpublished work are not verifiable.

The title accurately reflects the content, which covers the discovery, regulation, and function of the PI3K/AKT pathway in cancer.

8/10

The talk is delivered by a leading expert in the field (Alex Toker, professor at Harvard Medical School) and covers well-established knowledge as well as recent unpublished findings from his lab. The content is consistent with current scientific literature, but some claims about unpublished results and drug development are not independently verifiable.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to the PI3K/AKT pathway and its role in cancer.
• 05:00Overview of PI3K signaling and PIP3 as a second messenger.
• 10:00Discussion of AKT substrates and downstream effects.
• 15:00Frequency of PI3K pathway alterations in cancer.
• 20:00Timeline of PI3K and AKT inhibitor development.
• 25:00Challenges with current inhibitors: toxicities and resistance.
• 30:00Antibody-drug conjugates (ADCs) and high-DAR technology.
• 35:00PROTAC degraders of AKT and their advantages.
• 40:00Mutant-selective inhibitors and RAS-PI3K breakers.
• 45:00Synthetic lethal screens and combination strategies.

• Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002 — Mentioned as foundational work on PI3K signaling.
• Parsons R. PTEN and cancer. 1998 — Discovery of PTEN as a tumor suppressor.
• Dixon JE. PTEN as a lipid phosphatase. 1998 — Identification of PTEN lipid phosphatase activity.
• Staal SP. Molecular cloning of the akt oncogene. PNAS. 1987 — Discovery of AKT.
• Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017 — Review on AKT signaling.
• Alpelisib clinical trial (SOLAR-1) — Approval of alpelisib for breast cancer.
• Capivasertib clinical trial (CAPItello-291) — Approval of capivasertib for breast cancer.

• Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017 — Consistent with the speaker's description of AKT substrates.
• Fruman DA, et al. The PI3K pathway in human disease. Cell. 2017 — Supports the frequency of PI3K pathway alterations in cancer.

• None — No discordant sources mentioned.